IRCCS Humanitas Research Hospital

Running trials

• Not yet recruiting

  Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.

  NCT07927777· Phase 3· Istituto Oncologico Veneto IRCCS· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

  NCT07559175· Phase 2· Aimmune Nestlé Health Science US R&D, LLC· Source

• Not yet recruiting

  Nutritional Supplementation to Improve Colorectal Cancer Surgery

  NCT07599501· Istituto Clinico Humanitas· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  Photon-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM

  NCT07730203· Istituto Clinico Humanitas· Source

• Not yet recruiting

  A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36

  2025-522084-15-00· Phase 2/3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source

• Recruiting

  REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors

  NCT07635641· Istituto Clinico Humanitas· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Eli Lilly and Company· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases.

  NCT07577115· Istituto Clinico Humanitas· Source

• Recruiting

  Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

  NCT07413523· Istituto Clinico Humanitas· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Not yet recruiting

  PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

  NCT07207785· Phase 2· Fondazione Italiana Linfomi - ETS· Source

• Not yet recruiting

  Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction

  NCT07358247· Istituto Clinico Humanitas· Source

• Not yet recruiting

  XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

  NCT07381777· Phase 2· Gruppo Oncologico Italiano di Ricerca Clinica· Source

• Recruiting

  Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

  NCT07485296· Phase 2· Gruppo Oncologico del Nord-Ovest· Source

• Enrolling by invitation

  SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study

  NCT07116668· SafeHeal Inc· Source

• Not yet recruiting

  LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice

  NCT07336641· Fondazione ISIDE· Source

• Recruiting

  Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial

  NCT07299357· Istituto Clinico Humanitas· Source

• Recruiting

  Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

  NCT07330245· AstraZeneca· Source

• Recruiting

  Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment

  NCT07393360· Pharmanutra S.p.a.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

  NCT07137598· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

  NCT07389265· Phase 3· University of Campania Luigi Vanvitelli· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· BioNTech SE· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Recruiting

  A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

  NCT07073079· AbbVie· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

  NCT06821542· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)

  NCT06790251· F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore· Source

• Recruiting

  Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

  NCT05815927· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Pfizer· Source

• Recruiting

  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

  NCT06994143· Phase 1· Cullinan Therapeutics Inc.· Source

• Enrolling by invitation

  p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging

  NCT07603167· Humanitas University· Source

• Recruiting

  OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

  NCT06462963· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Recruiting

  PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial

  NCT06949254· Istituto Clinico Humanitas· Source

• Active, not recruiting

  Racial Disparities in Acute Stroke

  NCT06955442· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source

• Active, not recruiting

  Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)

  NCT05605899· Phase 3· Kite Pharma Inc.· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

  NCT06644781· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Photon-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary Fibrosis

  NCT07790614· Istituto Clinico Humanitas· Source

• Active, not recruiting

  Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

  NCT06716814· Phase 3· Swedish Orphan Biovitrum· Source

• Not yet recruiting

  Effects of Action Observation Training and Motor Imagery Delivered by Telerehabilitation in Patients with Parkinson's Disease

  NCT06814782· Istituto Clinico Humanitas· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

  NCT06717126· Phase 2· iOnctura· Source

Showing 50 of 254.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer19 recruiting
• Lung cancer16 recruiting
• Prostate cancer12 recruiting
• Childhood cancers10 recruiting
• Gastric and oesophageal cancer10 recruiting
• Head and neck cancer8 recruiting
• Metastatic breast cancer6 recruiting
• Sarcoma6 recruiting
• Bladder cancer4 recruiting
• Crohn's disease4 recruiting
• Liver and biliary tract cancer4 recruiting
• Pancreatic cancer4 recruiting
• Rheumatoid arthritis4 recruiting
• Endometrial cancer3 recruiting
• Glioblastoma3 recruiting
• Haemophilia3 recruiting
• Ovarian cancer3 recruiting
• Stroke3 recruiting
• Acute myeloid leukaemia2 recruiting
• Asthma2 recruiting
• Bronchiectasis2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Dilated cardiomyopathy2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Follicular lymphoma2 recruiting
• Hodgkin lymphoma2 recruiting
• Lupus (SLE)2 recruiting
• Mantle cell lymphoma2 recruiting
• Melanoma2 recruiting
• Neuroendocrine tumours2 recruiting
• Psoriasis2 recruiting
• Triple-negative breast cancer2 recruiting
• Ulcerative colitis2 recruiting
• Alopecia areata1 recruiting
• Amyloidosis1 recruiting
• Aortic stenosis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Cytomegalovirus infection1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Heart failure1 recruiting
• Hidradenitis suppurativa1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Myocarditis1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Parkinson disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriatic arthritis1 recruiting
• Thyroid cancer1 recruiting
• Ventricular tachycardia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· Phase 3· H e x a l AG· Source

• Completed

  Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A

  2023-505801-17-00· Phase 1· Swedish Orphan Biovitrum AB (publ)· Source

• Active, not recruiting

  RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

  NCT06243458· Phase 2· GCP-Service International West GmbH· Source

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Genentech Inc.· Source

• Completed

  A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

  2023-506881-30-00· Phase 1· H e x a l AG· Source

• Completed

  A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

  NCT06333860· Phase 4· AbbVie· Source

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Completed

  FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC

  2023-505145-93-00· Phase 1/2· Alentis Therapeutics AG· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

  NCT06058741· AbbVie· Source

• Recruiting

  A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

  NCT06145373· Phase 4· Sanofi· Source

• Recruiting

  Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

  NCT05934084· Fondazione Italiana Linfomi - ETS· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Sanofi· Source

• Completed

  Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

  NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source

• Completed

  A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

  NCT06208306· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Pfizer· Source

• Completed

  SafeHeal Diverting Ileostomy Pivotal Study

  NCT06152276· SafeHeal Inc· Source

• Withdrawn

  R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT05966233· Phase 2· Fondazione Italiana Linfomi - ETS· Source

• Terminated

  A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  NCT06039384· Phase 1· Incyte Corporation· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Sanofi· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Genmab A/S· Source

• Completed

  A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

  2023-503689-21-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Completed

  Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis

  2022-503005-38-00· Phase 2· Landos Biopharma Inc.· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer

  NCT05724602· Phase 2· European Organisation For Research And Treatment Of Cancer· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.

  2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  Immune Microenvironment and Gene Expression Profiling in Mesothelioma

  NCT06581549· Istituto Oncologico Veneto IRCCS· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Recruiting

  Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER)

  2022-502060-21-00· Phase 4· Octapharma AG· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

  2022-502057-33-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

  2022-502888-38-00· Phase 2· Eli Lilly & Co.· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· BeiGene· Source

• Active, not recruiting

  Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

  NCT05910528· Phase 2· Hoffmann-La Roche· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

  NCT05849922· Phase 2· Sanofi· Source

• Completed

  Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

  NCT03744468· Phase 1/2· Beigene Ltd.· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· AbbVie· Source

• Completed

  AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease

  NCT05471245· Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

  NCT05784597· Phase 1· Philogen S.p.A.· Source

• Terminated

  Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

  NCT05785715· Phase 2· AbbVie· Source

Showing 50 of 160.

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer121 works · 23 trials
• Colorectal cancer94 works · 32 trials
• Asthma90 works · 4 trials
• Prostate cancer65 works · 20 trials
• Ulcerative colitis63 works · 28 trials
• Bronchiectasis59 works · 6 trials
• Bladder cancer48 works · 12 trials
• Crohn's disease45 works · 17 trials
• Pancreatic cancer41 works · 11 trials
• Psoriasis33 works · 11 trials
• Atopic dermatitis (eczema)33 works · 11 trials
• Coronary artery disease32 works · 5 trials
• Neuroendocrine tumours29 works · 5 trials
• Systemic sclerosis (scleroderma)27 works · 1 trial
• Sarcoma25 works · 11 trials
• Primary biliary cholangitis20 works · 3 trials
• Myelodysplastic syndromes19 works · 13 trials
• Haemophilia17 works · 8 trials
• Aortic stenosis16 works · 1 trial
• Psoriatic arthritis15 works · 5 trials
• Hodgkin lymphoma14 works · 8 trials
• Head and neck cancer12 works · 19 trials
• Mesothelioma11 works · 8 trials
• Dilated cardiomyopathy9 works · 3 trials
• Myocarditis9 works · 1 trial
• Alopecia areata7 works · 3 trials
• Dystonia6 works · 1 trial
• Mantle cell lymphoma6 works · 7 trials
• Coeliac disease5 works · 0 trials
• Trigeminal neuralgia4 works · 1 trial